'Discovery to Delivery': How BPD Buy Helps MJH Bridge Science of Discovery With The Systems That Deliver Care

MJH Life Sciences’ acquisition of BPD Healthcare represents a major expansion of strategic capabilities for MJH across hospitals, health systems, and healthcare innovators — and leaders from both companies say the partnership is built on shared values and a common purpose: improving patient outcomes.

In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.

“This is about building alignment around one core goal, which is measurable impact on patient outcomes,” Hennessy said.

The companies plan to combine BPD’s proprietary data platform and precision marketing tools with MJH’s vast content network and clinical relationships to create a more integrated model for communication and engagement.

“Being able to bridge that gap is absolutely essential,” Hennessy said. “At the end of the day, it’s all about moving the needle for patients.”

Brown said BPD’s mission from the beginning was to serve “purpose-driven organizations” in the hospital and health system space. Over two decades, the company expanded into a data-driven, AI-enabled marketing and consulting partner for leading health systems nationwide.

When the time came to seek a long-term partner, Brown said MJH Life Sciences stood out. “Nobody had the purpose, nobody had the leadership, nobody else had the scale, and nobody else had the network of relationships that MJH brought to the table,” he said.

Watch the full interview above to hear how MJH and BPD plan to drive innovation “from discovery to delivery” across the healthcare ecosystem.